You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Title |
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial
|
---|---|
Published in |
Trials, April 2021
|
DOI | 10.1186/s13063-021-05180-1 |
Pubmed ID | |
Authors |
Murat Akova, Serhat Unal |
X Demographics
The data shown below were collected from the profiles of 84 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 12 | 14% |
Indonesia | 7 | 8% |
Canada | 5 | 6% |
Turkey | 3 | 4% |
Colombia | 2 | 2% |
Argentina | 2 | 2% |
North Macedonia | 1 | 1% |
Philippines | 1 | 1% |
Australia | 1 | 1% |
Other | 2 | 2% |
Unknown | 48 | 57% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 74 | 88% |
Scientists | 8 | 10% |
Science communicators (journalists, bloggers, editors) | 2 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 328 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 328 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 33 | 10% |
Student > Bachelor | 32 | 10% |
Researcher | 24 | 7% |
Student > Ph. D. Student | 21 | 6% |
Lecturer | 15 | 5% |
Other | 60 | 18% |
Unknown | 143 | 44% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 73 | 22% |
Nursing and Health Professions | 35 | 11% |
Biochemistry, Genetics and Molecular Biology | 11 | 3% |
Social Sciences | 11 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 2% |
Other | 40 | 12% |
Unknown | 151 | 46% |